⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GYRE News
Gyre Therapeutics, Inc. Common Stock
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
GYRE
Form 8-K
sec.gov
GYRE
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (NASDAQ:GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm
accessnewswire.com
GYRE
Form 8-K
sec.gov
GYRE
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
globenewswire.com
GYRE
Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
globenewswire.com
GYRE
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
globenewswire.com
GYRE
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
globenewswire.com
GYRE
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
globenewswire.com
GYRE